Generic name
Octreotide: adverse event reports filed with FDA
3,372 reports list it as a suspect or interacting product, 2004–2026. Class: Somatostatin analog. Also reported as Octreotide Injection, Octreotide 50mcg, Octreotide Inj 1000mcg.
- 3,372
- reports as suspect product
- 0% of all reports · about 155 a year
- 366
- reports, 12 months to June 2026
- 413 in the 12 months before
- 92.1%
- marked serious by the reporter
- 77.3% across the class
- 15.9%
- record death among outcomes, as reported
- 537 reports · not verified by FDA
Between October 2004 and June 2026, 3,372 adverse event reports received by FDA list octreotide, a generic name as a suspect or interacting product. Reports that mention it only as a concomitant medication (2,002) are left out of every figure here.
In the 12 months to June 2026, 366 reports listed it, down 11% from 413 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 155 reports a year and 0% of the 20,646,523 reports in the database, and 18.7% of the reports for the somatostatin analog class. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded drug ineffective (15.2%), off label use (11.7%) and diarrhoea (9%). A report can list several reactions, so shares add to more than 100%; 842 different terms appear across these reports. Drug ineffective is recorded in 15.2% of these reports, a larger share than in the median somatostatin analog drug (4.8%).
92.1% of the reports are marked serious by the reporter (77.3% across the class); 15.9% record death among the outcomes and 39.1% record hospitalisation, as reported. 45% of the reports came from other health professionals, and the largest patient age group is 45 to 64 (24.4%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Octreotide reports recording the termmedian drug in somatostatin analog
- Drug ineffectivethe medicine did not work as expected15.2%513
- Off label useused for a purpose or in a way not on the label11.7%393
- Diarrhoealoose or frequent stools9%304
- Deaththe patient died; cause not stated by this term8.1%272
- Nauseafeeling sick5.8%194
- Fatiguetiredness5.1%173
- Abdominal painstomach or belly pain3.7%124
- Hypoglycaemialow blood sugar3.7%124
- Weight decreasedweight loss3.3%112
- Product use in unapproved indicationused for a purpose not on the label3.2%108
- Disease progressionthe disease advanced3.1%104
- Painpain, site not specified3.1%104
- Condition aggravatedthe condition being treated got worse3%101
- Vomitingbeing sick2.9%98
- Headachehead pain2.7%92
- Therapy non-responderthe treatment did not work2.7%92
- Dyspnoeashortness of breath2.7%90
- Malaisegeneral feeling of being unwell2.6%88
- Dizzinesslight-headedness or unsteadiness2.6%87
- Metastases to liver2.5%84
- Flushingsudden reddening or warmth of the skin2.4%80
- Hypertensionhigh blood pressure2.3%79
- Decreased appetitereduced appetite2.3%78
- Injection site painpain where the injection was given2.3%78
- Astheniaweakness or lack of energy2.3%77
- Product use issuea problem in how the product was used2.3%77
- Blood pressure increaseda raised blood pressure reading2.2%75
- Falla fall2%66
Top 30 of 842 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 6 drugs in the somatostatin analog class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 18,073 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 42.8% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Carcinoid tumour | 213 | 6.3% |
| Acromegaly | 166 | 4.9% |
| Neuroendocrine tumour | 120 | 3.6% |
| Hypoglycaemia | 100 | 3% |
| Diarrhoea | 74 | 2.2% |
| Hyperinsulinism | 71 | 2.1% |
The indication field is filled in by the reporter and is often blank; shares are of all 3,372 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Octreotide reports |
|---|---|---|
| Sandostatin LAR Depot | 182 | 5.4% |
| Pantoprazole | 166 | 4.9% |
| Everolimus | 164 | 4.9% |
| Dextrose | 114 | 3.4% |
| Dexamethasone | 111 | 3.3% |
| Capecitabine | 96 | 2.8% |
| Lutathera | 92 | 2.7% |
| Furosemide | 86 | 2.6% |
| Prednisone | 81 | 2.4% |
| Loperamide | 79 | 2.3% |
Other products listed in reports where Octreotide is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Octreotide | Somatostatin analog | All reports |
|---|---|---|---|
| Reports as suspect product | 3,372 | 18,073 | 20,646,523 |
| Share of that pool | — | 18.7% | 0% |
| Reports, latest 12 months | 366 | — | 1,332,454 |
| Marked serious | 92.1% | 77.3% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 159 | 190 | 91 |
| Hospitalisation recorded, per 1,000 reports | 391 | 318 | 213 |
| Consumer-filed share | 24.6% | 41.8% | 45.8% |
| Top term, share of reports | Drug ineffective 15.2% | median 4.8% | 6.3% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the somatostatin analog class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Sandostatin | brand | 5,413 | 71 | 90.3% |
| Somatuline Depot | brand | 4,295 | 127 | 35.3% |
| Lanreotide acetate | generic | 3,005 | 690 | 93.9% |
| Octreotide acetate | generic | 1,227 | 120 | 88.9% |
| Signifor | brand | 761 | 42 | 73.5% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Octreotide reports
How many adverse event reports has FDA received for Octreotide?
3,372 reports list Octreotide as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 366 of them arrived in the latest 12 months. Another 2,002 list it only as a concomitant medication.
What reactions are recorded in Octreotide reports?
drug ineffective (15.2%), off label use (11.7%), diarrhoea (9%), death (8.1%) and nausea (5.8%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Octreotide was responsible.
How serious are the reports?
92.1% are marked serious by the reporter. Among the outcomes recorded, 15.9% of reports include death and 39.1% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
other health professional (45%), consumer or non-health professional (24.6%) and physician (23.4%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Octreotide rising?
366 reports in the 12 months to June 2026, down 11% from 413 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Octreotide was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Octreotide?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Octreotide as a suspect or interacting product; reports listing it only as a concomitant medication (2,002) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.